Kiora receives Nasdaq deficiency notice for bid price below $1.00; CFO resigns

KIORA PHARMACEUTICALS INC

Nasdaq notified Kiora on Feb 23, 2022 that its stock closed below $1.00 for 30 consecutive business days.
Company has 180 days (until Aug 22, 2022) to regain compliance by closing >= $1.00 for at least 10 consecutive trading days.
CFO Sarah Romano resigned effective Feb 25, 2022; Corporate Controller Michael Meluzio appointed as principal financial and accounting officer.
Kiora evaluating options to regain compliance; may seek additional 180-day period if eligible.

item 3.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sarah Romano

Chief Financial Officer

KPRX · KIORA PHARMACEUTICALS INC

Effective: 2022-02-25
Successor: Michael Meluzio
Filed: February 28, 2022, 6:59 PM ET

Sarah Romano resigned as Chief Financial Officer of the Company effective as of February 25, 2022

Appointed

Michael Meluzio

principal financial officer and principal accounting officer

KPRX · KIORA PHARMACEUTICALS INC

Effective: 2022-02-25
Filed: February 28, 2022, 6:59 PM ET

the Company appointed Michael Meluzio, CPA, the Corporate Controller of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sarah Romano resigned as Chief Financial Officer at KIORA PHARMACEUTICALS INC.

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Sarah Romano resigned as Chief Financial Officer of the Company effective as of February 25, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Meluzio was appointed as principal financial officer and principal accounting officer at KIORA PHARMACEUTICALS INC.

Action: appointed
Role: principal financial officer and principal accounting officer

Exact text from the filing

the Company appointed Michael Meluzio, CPA, the Corporate Controller of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Date.

View on SEC.gov

KIORA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-22-028121

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.